CSTLCastle Biosciences, Inc.

$805M

Q1 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$27M+17.7% YoY

Gross Profit

$21M77.9% margin

Operating Income

-$25M-91.3% margin

Net Income

-$25M-91.7% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$444M

Total Liabilities

$47M

Stockholders' Equity

$397M

Cash & Equivalents

$309M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$23M	+17.7%
Gross Profit	$21M	$20M	+5.7%
Operating Income	-$25M	-$4M	-472.3%
Net Income	-$25M	-$4M	-475.3%

Revenue Segments

Dermatologic

$24M91%

Service, Other

$3M9%

CSTL Q1 2022 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena